Highlighting recent clinical trial data on pirtobrutinib in patients with chronic lymphocytic leukemia, the panel shares their experience utilizing it in clinical practice. This is a modal window. This video is either unavailable or not supported in this browser Error Code: MEDIA_ERR_SRC_NOT_...
“Efficacy outcomes were similar in the full study population, [those with] relapsed or refractory CLL or SLL after prior BTK inhibition, demonstrating a clinical benefit of liso-cel in this broader population,” the study authors wrote. In the full study population, the IRC-assessed CR/CRi ra...
With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer Network guidelines, this approval reinforces cabozantinib’s role in improving outcomes for patients facing these challenging cancers. October 3rd 2024 Dr Rick Chapman Discusses Key ...
Clinical trials How do novel agents (alone or in combination) compare with FCR, BR or O+C? 1L R/R Reported at ASH 2018 EMA approved, undergoing NICE appraisal O+C O+I O+V iLLUMINATE CLL14 BR I+R I US Alliance FCR I+R FCR FLAIR ECOG I+R I I+V R/R BR V+R Reported at AS...
Dr. Diefenbach added that, although CAR T-cell therapy can help some of these patients, it has not shown to be as effective in CLL as it is in non-Hodgkin lymphoma. ONC Alerts - Essential Updates Latest oncology breakthroughs, policy changes, and industry trends. Choose your topics an...
Clinical development of vecabrutinib has not proceeded beyond the phase 1 trial, which demonstrated insufficient activity to justify further development in B-cell malignancies.55 An intriguing new molecule, with early results presented at ASH, is LP-168, which binds wild-type BTK covalently and ...
(CLL), treatment with acalabrutinib (Calquence) was found to be non-inferior to treatment with ibrutinib (Imbruvica) in terms of progression-free survival (PFS), meeting the primary end point of the phase 3 ELEVATE-RR clinical trial (NCT02477696), according to a press release ...
The phase 1 TRANSCEND CLL 004 trial is evaluating the efficacy and safety of liso-cel monotherapy or with concurrent ibrutinib in patients with relapsed/refractory CLL. Most recently, in data presented at the International Workshop on CLL, the combination was associated with a manageable safety pro...
Blogs Breast Cancer Webinar Series Cancer Horizons Clinical Trial Corner Heal® Publications VideosCLL > All SubspecialtiesCURE’s Chronic Lymphocytic Leukemia (CLL) page features the latest cancer news and updates on CLL Through articles, videos, podcasts, and more, CURE brings readers the insights...
By being a part of a clinical trial you might be receiving, we hope, the next best treatment for that disease that will hopefully lead to an approval for the drug for everybody else with CLL, or with a different disease. And it may be advancing, because then this will lead to us ...